RedHill Biopharma (RDHL) Current Assets (2012 - 2025)

RedHill Biopharma (RDHL) has 14 years of Current Assets data on file, last reported at $6.5 million in Q4 2025.

• Current Assets for Q4 2025 came in at $6.5 million, down 45.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.5 million (down 45.19% YoY), and the FY2025 annual result was $6.5 million, down 45.19% from the prior year.
• Current Assets declined to $6.5 million in Q4 2025 per RDHL's latest filing, from $12.6 million in the prior quarter.
• Over five years, Current Assets peaked at $98.5 million in Q2 2021 and troughed at $6.5 million in Q4 2025.
• A 5-year average of $45.5 million and a median of $21.6 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2021 and 2023: Current Assets soared 61.13% in 2021, then tumbled 81.21% in 2023.
• A 5-year view of Current Assets shows it stood at $89.2 million in 2021, then fell by 3.65% to $85.9 million in 2022, then plunged by 81.21% to $16.1 million in 2023, then decreased by 26.2% to $11.9 million in 2024, then tumbled by 45.19% to $6.5 million in 2025.
• Business Quant data shows RDHL's Current Assets at $6.5 million in Q4 2025, $12.6 million in Q2 2025, and $11.9 million in Q4 2024.